Introduction
============

In the past 10-15 years, major advances have been made in prenatal screening for Down's syndrome,[@ref1] [@ref2] the foremost known genetic cause of mental retardation.[@ref3] It has been suggested that maternal age alone as a screening strategy should be abandoned,[@ref4] but there is still no consensus on the most cost effective alternative, and thus no national strategy exists in the United States or Canada.[@ref5] [@ref6]

New strategies that allow a relatively high detection rate combine analyses from first and second trimesters of pregnancy.[@ref7] [@ref8] Different approaches have been proposed[@ref6] [@ref7] [@ref9] such as

-   The integrated test, in which the results from first trimester screening tests are not analysed until the results from second trimester tests are evaluated, when both sets are assessed together[@ref1]

-   Sequential screening, in which first trimester screening results determine whether second trimester testing is indicated: women with a positive first trimester result are offered invasive testing (chorionic villous sampling), whereas those with a negative result are offered another serum test[@ref10]

-   Contingent screening, in which the first trimester screening results are used to categorise women as high, intermediate, or low risk.[@ref11] High risk women are offered early diagnosis (chorionic villous sampling), low risk women are reassured and do not undergo second trimester testing, and intermediate risk women are offered second trimester testing. The cut-off values between the risk categories vary depending on how the groups are defined.

Published evaluations of screening programmes for Down's syndrome have primarily focused on the detection rates of the different strategies used.[@ref6] Although the detection rate is important for individuals, the cost effectiveness ratio and similar end points of screening strategies are needed for the development of optimal public health strategies.[@ref6] In that respect, only contradictory and limited data exist on the three above methods of combining first and second trimester tests.[@ref6] [@ref9] Using a decision analysis model based on data from the First and Second Trimester Evaluation of Risk (FASTER) trial,[@ref12] Ball et al reported that contingent screening dominated (lower costs with better outcomes) the integrated test.[@ref6] In contrast, Wald et al---summarising the modelling of integrated, sequential, and contingent screening strategies from data derived from the Serum Urine and Ultrasound Screening Study (SURUSS)[@ref13]---concluded that integrated screening had the best screening performance.[@ref9] However, recent reports underline the insufficiency of data on these three screening strategies.[@ref5] [@ref9] [@ref14] For sequential and contingent testing, there is no consensus on cut-off levels, resulting in variations in performance measured.[@ref8] A workshop of experts convened by the National Institutes of Health concluded that the contingent screening strategy needed further study before its widespread implementation could be recommended.[@ref8]

Given the countless screening strategies available,[@ref7] [@ref15] regional differences in local resources,[@ref5] [@ref16] and the costs of prospective clinical studies,[@ref17] no empirical study can be foreseen that would compare all options available for the three approaches to combining first and second trimester analyses. There are indeed too many possible combinations of tests, sequences, cut-off values, and schedules to be handled in a single study. Only computer simulations can compare all the options to identify the most cost effective.[@ref6] [@ref9] [@ref17] [@ref18] [@ref19]

In the current analysis, we performed computer simulations to compare 19 different screening options based on the three screening approaches (integrated test and sequential and contingent screenings) with various cut-off levels and using real data from the SURUSS trials.[@ref9] [@ref13] Our aims were to

-   Analyse the cost effectiveness ratio of the different screening options from a public health perspective

-   Compare their performance estimates for an overall 90% detection rate by evaluating seven other relevant end points that cover the main outcomes in prenatal screening for Down's syndrome[@ref9] [@ref17]:

    1.  1\) False positive rate that defines the number of scheduled amniocentesis procedures

    2.  2\) Number of procedure related miscarriages of normal (euploid) fetuses

    3.  3\) Number of live births with Down's syndrome

    4.  4\) Number of unnecessary terminations

    5.  5\) Proportion of pregnancies affected by Down's syndrome that were screened by a first trimester test

    6.  6\) Proportion of patients reassured early in gestation by first trimester testing

    7.  7\) Proportion of continuing pregnancies that proceed to a second trimester test

-   Compare the effects of eight different first trimester cut-off values in contingent and sequential screening strategies to determine the optimal value.

Material and methods
====================

Screening strategies and tests
------------------------------

The screening strategies considered were the integrated test, sequential screening, and contingent screening compared with maternal age alone (≥35 years), which has been the standard since antenatal diagnosis guidelines for invasive testing were established in the US in the late 1970s,[@ref20] and the triple test, which has been widely available in Europe and Canada since 1991.[@ref8] [@ref16] [@ref21] The box gives further details of the screening strategies and the tests used.

### Definitions of screening procedures

#### Integrated test

Measurements performed at different times of pregnancy are integrated into a single test result. Unless otherwise qualified, it refers to the integration of nuchal translucency measurement (by ultrasound scan of the width of an area of translucency at the back of the fetal neck) and measurement of pregnancy associated plasma protein A (PAPP-A) in the first trimester with the quadruple test markers in the second trimester (measurement of maternal serum concentrations of α fetoprotein, unconjugated oestriol, free or total β human chorionic gonadotrophin, and inhibin A) together with maternal age.

#### Sequential screening

First trimester tests are performed (nuchal translucency measurement and PAPP-A) and interpreted immediately. If the result is positive, the mother is offered a diagnostic test (chorionic villous sampling), but if it is not positive, second trimester serum markers (quadruple test markers) are measured and the results combined with the first trimester results to form an integrated test.

#### Contingent screening

First trimester tests (nuchal translucency measurement and PAPP-A) are used to categorise pregnant women as high, low, or intermediate risk. High risk women (positive result) are immediately offered a diagnostic test (chorionic villous sampling), low risk women (negative test result) receive no further screening, and intermediate risk women (lower risk positive result) undergo second trimester screening (quadruple test markers) for an integrated test to be done.

#### Triple test

Second trimester test based on the measurement of maternal serum α fetoprotein, unconjugated oestriol, and free or total β human chorionic gonadotrophin, together with maternal age.

Sequential and contingent screening strategies consist of a sequence of tests with many possible cut-off values for the risk of the fetus having Down's syndrome, but screening performance has been reported for only eight different cut-off points for first trimester tests (1 in 6, 1 in 9, 1 in 30, 1 in 58, 1 in 114, 1 in 175, 1 in 237, and 1 in 307).[@ref9] We compared 19 screening algorithms comprised possible screening scenarios resulting from the three screening strategies (integrated test and sequential and contingent screening), different cut-off values for contingent and sequential screenings, the triple test, and maternal age alone. For contingent screening, we also used a lower risk cut-off of 1 in 2000.

Diagnostic tests
----------------

The diagnostic procedures included in our simulation were conditional on the stage of pregnancy in accordance with best practice in prenatal care. Thus, amniocentesis was used for prenatal diagnosis only after second trimester screenings results, whereas women with a positive result at the first trimester screening were considered for transabdominal chorionic villous sampling for caryotyping. Timing of procedure-related euploid miscarriages is dependent on the test undergone. Our computer model also accounted for the performance characteristics of the diagnostic tests (amniocentesis and chorionic villous sampling).

Decision model
--------------

We developed a computer program in C11 language that simulates all 19 screening scenarios. The program was devised to

-   Generate a virtual population with characteristics related to the prevalence and clinical course of pregnancies affected by Down's syndrome and unaffected pregnancies, as well as maternal age distribution

-   Construct the various screening algorithms for the screening and diagnosis options for Down's syndrome

-   Simulate screening of this virtual population with each algorithm and measure pregnancy outcomes

-   Establish the direct healthcare costs of each screening option using costs of procedures and of complications provided by the Ministry of Health.

Figure 1[](#fig1){ref-type="fig"} shows a simplified version of the decision model. The model includes several possible outcomes of screening and diagnostic testing decisions, including birth of a baby with no chromosomal disorder, birth of a baby with Down's syndrome, miscarriage, elective abortion after positive test results, and whether a pregnancy loss occurs after a diagnostic test.

![**Fig 1** Simplified version of the decision model for screening options (panel A) and diagnosis procedure (panel B) used in computer simulation of prenatal screening strategies for Down's syndrome. Not shown, but included in the real model, is the possibility that miscarriage occurs before testing or after test results are known](gekj586503.f1){#fig1}

Data used in analysis
---------------------

Table 1[](#tbl1){ref-type="table"} lists all the input variables and their data sources. Table 2[](#tbl2){ref-type="table"} shows the demographic characteristics of the virtual population used in our computer simulation and the most critical assumptions. Our virtual population of 110 948 pregnancies corresponded to all pregnancies in Québec province in year 2001[@ref22] [@ref23] with the same maternal age distribution. This population was of mixed origins, mainly white, and table 2 contains details of maternal ages.

###### 

 Input variables used in computer simulation of 19 different screening options in prenatal screening for Down's syndrome

  Input variables                                                  Value                         Data sources
  ---------------------------------------------------------------- ----------------------------- ----------------------------------------------------------
  **Costs of procedures**                                          **Costs (\$C)\***             
  Integrated test                                                  65.00                         MSSS (2005),^30^ (2007),^31^ RAMQ (2007)^33^
  Sequential screening                                             105.00                        
  Contingent screening                                             55.00                         
  Triple test                                                      15.00                         
  Consulting with a genetic counsellor                             73.90                         RAMQ (2007)^33^
  Chorionic villous sampling                                       876.00                        MSSS (2005),^30^ (2007),^31^ RAMQ (2005),^33^ (2007)^33^
  Amniocentesis                                                    500.00                        
  Termination of pregnancy                                         1357.33                       MSSS (2003)^29^
  **Screening tests with 90% detection rate**                      **False positive rate (%)**   
  Integrated test (1/245 cut-off value)                            2.60                          Wald et al (2003)^13^
  Sequential screening, cut-off values for first trimester test:                                 Wald et al (2006)^9^
   1/6                                                             2.11                          
   1/9                                                             2.12                          
   1/30                                                            2.25                          
   1/58                                                            2.46                          
   1/114                                                           2.97                          
   1/175                                                           3.65                          
   1/237                                                           4.42                          
   1/307                                                           5.23                          
  Contingent screening, cut-off values for first trimester test:                                 Wald et al (2006)^9^
   1/6                                                             2.29                          
   1/9                                                             2.29                          
   1/30                                                            2.42                          
   1/58                                                            2.62                          
   1/114                                                           3.11                          
   1/175                                                           3.74                          
   1/237                                                           4.47                          
   1/307                                                           5.27                          
  Triple test (1/690 cut-off value)                                14.70                         Wald et al (2003)^13^

\*Canadian dollars (\$C), exchange rate in 2007: \$C1.0748=\$US1.00.

###### 

 Demographic characteristics of the population and the most critical assumptions used in computer simulation of 19 different screening options in prenatal screening for Down's syndrome

  Characteristics                                                                   Value     Data sources
  --------------------------------------------------------------------------------- --------- -----------------------------------------------------------------
  **Population simulated**                                                                    
  Total No of pregnant women                                                        110 948   MSSS (2007)^23^
  No of pregnancies affected by Down's syndrome:                                              AETMIS (2003),^22^ Snijders (1999),^27^ Morris et al (1999)^55^
   At first trimester                                                               290       
   At second trimester                                                              190       
   At third trimester                                                               140       
   At birth                                                                         131       
  No of women by age (years):                                                                 MSSS (2007)^23^
   \<20                                                                             9 008     
   20-24                                                                            24 987    
   25-29                                                                            33 421    
   30-34                                                                            27 320    
   35-39                                                                            13 135    
   40-44                                                                            2 925     
   ≥45                                                                              157       
   \<35 years old                                                                   94 735    
   ≥35 years old                                                                    16 213    
  Mean maternal age (years)                                                         27        
  **Assumed probabilities (%)**                                                               
  Consent to participate in prenatal screening                                      70.0      Forest et al (2004)^28^
  Consent for amniocentesis or chorionic villous sampling with screening positive   90.0      
  Fetal loss from amniocentesis                                                     0.5       AETMIS (2003),^22^ Sundberg et al (1997),^56^ CETS (1997)^57^
  Fetal loss from chorionic villous sampling                                        1.6       
  Proportion who terminated pregnancy with fetal Down's syndrome                    90.0      Forest et al (2004)^28^

Probabilities
-------------

*Pregnancies affected by Down's syndrome and risk of miscarriage---*We estimated the risk of a pregnancy being affected by Down's syndrome by multiplying the specific odds by maternal age of having an affected live birth[@ref24] [@ref25] (corrected for the spontaneous miscarriage of fetuses with Down's syndrome[@ref26] [@ref27]) by the likelihood ratio (for a given set of marker values) obtained from the overlapping multivariate Gaussian distributions of marker levels in affected and unaffected pregnancies.[@ref9] If a woman chooses to undergo amniocentesis, she is at risk of a miscarriage before she has the test and either before or after the test results are given.

*Test performance---*We used the distribution of marker values in pregnancies affected by Down's syndrome and in unaffected pregnancies reported in the SURUSS trials to determine the parametric values (means, standard deviations, correlation coefficients, and truncation limits).[@ref9] [@ref13] We included rates of false positive and false negative test results in the calculations.

*Other probabilities---*Our simulation included the level of compliance previously estimated in the Québec population[@ref28]---that is, the proportion of women who consent to participate in prenatal screening for Down's syndrome and to a diagnostic test after a positive screening result. We also included the chance that a woman will choose elective abortion after a positive diagnostic test.[@ref28]

Costs
-----

In Canada, in accordance with the Canadian Health Care Act, all services considered as medically necessary are generally provided exclusively inside the public healthcare system and are free of charge. We considered only direct costs under the Ministry of Health and the Public Medical Assurance perspectives. Unit prices were averages for Quebec province calculated from government databases (financial and operative databank SIFO and APR-DRG). Costs for laboratory and imaging tests were from technical units for Quebec province.[@ref29] [@ref30] [@ref31] [@ref32] [@ref33] These unit prices include the costs of necessary support services (such as administration, security, cleaning, etc).[@ref34] Items considered for costing comprised screening costs and medical services related to the following outcomes---birth, spontaneous miscarriage, elective abortion after positive test results, or pregnancy loss after a diagnostic test. Costs are expressed in Canadian dollars (\$C) at 2007 values (exchange rate: \$C1.0748=\$US1.00).

Cost effectiveness analysis
---------------------------

Our approach follows guidelines for cost effectiveness analysis in prenatal diagnosis.[@ref17] The analyses were run to evaluate global costs, cost effectiveness ratios (costs per case of Down's syndrome diagnosed), and incremental cost effectiveness ratios comparing all 19 screening options. Incremental cost effectiveness ratio was calculated by dividing the difference in cost between each screening strategy and screening based on maternal age only (amniocentesis for women aged ≥35 years) by the difference in the number of cases of Down's syndrome detected by the two strategies. The incremental cost effectiveness ratio therefore represents the additional cost or savings per additional abnormality detected. All measured costs occurred within one year; and so there was no need to discount costs and effects over time.[@ref17]

Sensitivity analyses
--------------------

In order to test the robustness of our findings, we performed a series of simulations (univariate sensitivity analyses) in which we varied the major assumptions of the modelling with values proposed in the AETMIS report[@ref22] and recalculated the cost effectiveness ratios.[@ref17] Apart from the values shown in tables 1[](#tbl1){ref-type="table"} and 2[](#tbl2){ref-type="table"}, we also tested the effects of

-   Rates of consent to participate in prenatal screening of 65% and 80%[@ref22]

-   Rates of fetal loss from chorionic villous sampling of 0.5%, 1%, and 2%, and from amniocentesis of 1% and 1.5%[@ref22]

-   The proportion of couples with a fetus with confirmed Down's syndrome who would undergo pregnancy termination, namely 70% and 80%

-   Varying the sensitivities and false positive rates of the screening strategies over the ranges achieved in the SURUSS trial.[@ref9] [@ref13]

Estimation of confidence intervals
----------------------------------

In order to generate 95% confidence intervals for our estimates of cost effectiveness ratios, we used the method of replications.[@ref35] This consisted of simulating each screening option 100 times on a virtual population of 110 948 pregnancies (100×110 948 individuals). It resulted in more than 11 million individuals being screened for computing the mean cost effectiveness ratios for each screening scenario.

Results
=======

Cost effectiveness analysis
---------------------------

Table 3[](#tbl3){ref-type="table"} summarises the results of our cost effectiveness analysis. The most cost effective screening strategy seems to be contingent screening (cost effectiveness ratio \$C26 833 per case of Down's syndrome with a high risk cut-off value of 1 in 30). These results were robust in sensitivity analyses: none of these different models yielded a different relative rank of the various screening scenarios analysed. Compared with the reference screening strategy (maternal age only), the incremental cost effectiveness ratio of contingent screening (with cut-off value of 1 in 6) is −\$C30 963 per averted birth with Down's syndrome. The estimated costs per prevented birth with Down's syndrome were \$C35 215 for sequential screening, \$C38 944 for integrated screening, and \$C43 809 for the triple test. Consequently, the contingent screening strategy seems to be most cost effective. As expected, amniocentesis based on advanced maternal age only is the least cost effective option, with a cost effectiveness ratio of \$C74 037 per case of Down's syndrome.

###### 

 Cost effectiveness analysis of different screening options in prenatal screening for Down's syndrome\*

  Screening options                                                Global costs (\$Cmillions)†   Effectiveness‡   Cost effectiveness ratio   Incremental cost effectiveness ratio
  ---------------------------------------------------------------- ----------------------------- ---------------- -------------------------- --------------------------------------
  Amniocentesis for women ≥35 years old                            4.1549                        56.12            74 037                     1.00
  Contingent screening, cut-off values for first trimester test:                                                                             
   1/6                                                             2.7529                        101.40           27 149                     −30 963
   1/9                                                             2.7630                        102.48           26 961                     −30 025
   1/30                                                            2.8579                        106.51           26 833                     −25 739
   1/58                                                            2.9960                        108.67           27 570                     −22 054
   1/114                                                           3.2596                        109.72           29 708                     −16 704
   1/175                                                           3.5509                        111.69           31 792                     −10 871
   1/237                                                           3.8494                        111.61           34 490                     −5 506
   1/307                                                           4.1999                        112.72           37 260                     795
  Sequential screening, cut-off values for first trimester test:                                                                             
   1/6                                                             3.6265                        100.88           35 949                     −11 805
   1/9                                                             3.6400                        101.63           35 816                     −11 315
   1/30                                                            3.7440                        106.32           35 215                     −8 185
   1/58                                                            3.8662                        109.07           35 447                     −5 453
   1/114                                                           4.1326                        108.78           37 991                     −423
   1/175                                                           4.4416                        112.37           39 526                     5 096
   1/237                                                           4.7597                        110.62           43 027                     11 096
   1/307                                                           5.0960                        112.46           45 314                     16 704
  Integrated test                                                  3.3944                        87.16            38 944                     −24 502
  Triple test                                                      3.8324                        87.48            43 809                     −10 285

\*Values are per 100 000 pregnancies in prenatal care for an overall 90% detection of cases of Down's syndrome.

†Canadian dollars (\$C), exchange rate in 2007: \$C1.0748=\$US1.00.

‡No of cases of Down's syndrome detected by screening test.

Screening strategies outcomes
-----------------------------

Depending on the specific end points that are considered, different screening approaches may seem more appropriate. The most appropriate screening test for Down's syndrome should have the lowest false positive rate (to minimise the number of invasive procedures required and their related complications), the highest detection rate, and the best cost effectiveness ratio.[@ref16] The screening procedure (non-invasive screening and diagnostic technique) may also interfere with the number of live births with Down's syndrome. Figure 2[](#fig2){ref-type="fig"} shows the effects of the different screening strategies on these major end points---false positive rate, number of procedure-related euploid miscarriages, and number of live births with Down's syndrome.

![**Fig 2** Effects of different prenatal screening strategies for Down's syndrome on (A) rate of false positive results, (B) number of procedure related euploid miscarriages, and (C) number of live births with Down's syndrome (all values are per 100 000 pregnancies)](gekj586503.f2){#fig2}

Early diagnosis of pregnancies affected by Down's syndrome may result in unnecessary terminations since some of the affected fetuses would be spontaneously aborted before term.[@ref9] Some studies have suggest that, in order to avoid this problem, women prefer a lower false positive rate,[@ref36] [@ref37] but others suggest that women want early diagnosis.[@ref38] [@ref39] We evaluated the effect of the different screening strategies on this issue by calculating the number of unnecessary terminations, the proportion of pregnancies affected by Down's syndrome screened by a first trimester test, and the proportion of continuing pregnancies that proceed to a second trimester test (fig 3[](#fig3){ref-type="fig"}).

![**Fig 3** Effects of different prenatal screening strategies for Down's syndrome on (A) number of unnecessary terminations, (B) proportion of pregnancies affected by Down's syndrome screened by a first trimester test, and (C) proportion of continuing pregnancies that proceed to a second trimester test (all values are per 100 000 pregnancies)](gekj586503.f3){#fig3}

Contingent and sequential screening strategies produced similar results on the major outcomes---respectively, 1.43% and 1.55% for false positive results (fig 2[](#fig2){ref-type="fig"}), six procedure related euploid miscarriages each (fig 2[](#fig2){ref-type="fig"}), 16 unnecessary terminations each (fig 3[](#fig3){ref-type="fig"}), and 43.71% and 44.13% of affected pregnancies with a positive first trimester test (fig 3[](#fig3){ref-type="fig"}) (these results are those achieved with the most favourable cut-off value). However, contingent screening was unique in permitting 77.81% of patients to be reassured at the first trimester and 77.95% of women to avoid retesting in the second trimester (proportion of continuing pregnancies that proceed to a second trimester testing, fig 3[](#fig3){ref-type="fig"}). Indeed, contingent screening (whatever the cut-off value) allowed about 78% of women (77.75% to 78.51%) to be reassured with a negative screening result early in gestation, which was obviously not possible integrated, sequential, or triple test screening strategies.

In the same manner, we found that integrated screening was associated with a low number of procedure related euploid miscarriages (n=6, fig 2[](#fig2){ref-type="fig"}) and, in conjunction with the triple test, gave the best result for unnecessary terminations (n=6 for both, fig 3[](#fig3){ref-type="fig"}). Moreover, the integrated test's false positive rate is close to those achieved by sequential and contingent screening (1.82%, 1.43%, and 1.55% respectively, fig 2[](#fig2){ref-type="fig"}).

Impact of cut-off values in first trimester screening
-----------------------------------------------------

We simulated the use of different cut-off values for the risk of a fetus having Down's syndrome in the first trimester tests of the contingent and sequential screening strategies. For both contingent and sequential screening, these had significant effects on

-   Cost effectiveness ratios (from \$C26 833 to \$C37 260 and from \$C35 215 to \$C45 314 per case of Down's syndrome respectively, table 3[](#tbl3){ref-type="table"})

-   False positive rate (1.55% to 3.69% and 1.43% to 3.66%, fig 2[](#fig2){ref-type="fig"})

-   Number of procedure related euploid miscarriages (6 to 46 and 6 to 45, fig 2[](#fig2){ref-type="fig"})

-   Number of unnecessary terminations (16 to 26 and 16 to 25, fig 3[](#fig3){ref-type="fig"})

-   Proportion of affected pregnancies with a positive result from the first trimester test (44.1% to 86.1% and 43.7% to 86.3%, fig 3[](#fig3){ref-type="fig"}).

Discussion
==========

Limitations of study
--------------------

Our results are based on mathematical modelling and not on prospective observational data. However, we used empirical data and true healthcare costs as input parameters for the simulations. Given geographical limitations, resource differences between regions, and the many possible screening strategies for Down's syndrome, it is unlikely that a large scale, comprehensive, prospective, clinical trial could be organised across North America. Our approach was useful in allowing 19 different strategies to be assessed and compared simultaneously.[@ref18] [@ref40] [@ref41] [@ref42]

Our reported cost effectiveness ratios were based on Québec province's healthcare system and costs. However, given the robustness of our findings observed in the sensitivity analyses (in which we varied the values of the major assumptions of the modelling), our conclusions are likely to be applicable to other jurisdictions. The demographic characteristics of the population we simulated are similar to those of other Western countries. In particular, the mean maternal age and the proportion of women aged ≥35 years were similar to those of the populations of the SURUSS and the FASTER trials, which represented women in the UK and US.[@ref12] [@ref13] The effect of the maternal age distribution on the detection rate of Down's syndrome is reported to be limited and unlikely to be large enough to influence screening policy decisions.[@ref43] Also, pregnancy outcomes are likely to be similar across different populations. With respect to healthcare costs, they could be estimated for other provinces by using other costs units in the simulation model.

Most improvements in overall cost effectiveness attained with a screening strategy are due to the reduction in live births with Down's syndrome.[@ref18] An important drawback of studies that incorporate the future costs of caring for a child with Down's syndrome into their cost effectiveness or cost utility analyses[@ref6] [@ref44] is that they do not incorporate commensurate benefits of having such a child.[@ref45] In accordance with previous reports,[@ref9] [@ref46] [@ref47] [@ref48] we decided not to consider the cost of caring for a child with Down's syndrome. However, computing the cost per case of Down's syndrome detected allows us to compare different screening strategies on a common ground.

Our study did not consider the logistical problems and costs of implementing a screening strategy that includes nuchal translucency measurement or chorionic villous sampling in North America.[@ref8] [@ref15] Neither technique is universally available throughout the US and Canada,[@ref15] [@ref18] and the cost of establishing a screening programme with mandatory use of the techniques, including its administrative and technical challenges, is unknown.[@ref15] [@ref50] Because of this, some have speculated that such a screening programme is not justifiable[@ref15] or has serious implications for resource use.[@ref16]

Cut-off values for contingent and sequential screening options
--------------------------------------------------------------

There is no consensus on what are the most appropriate cut-off values for high risk in the first trimester tests for contingent and sequential screening strategies,[@ref8] even though they could have a major effect on screening performance.[@ref6] [@ref9] Our data show the impact of modulating the cut-off values and confirm that, for risk assessment to be successful, a careful choice of cut-off is required.

The first aim of using non-invasive screening is to reduce the number of procedure related euploid miscarriages.[@ref50] Our analysis suggests that first trimester cut-off values for high risk of 1 in 6 and 1 in 9 are most appropriate because they lead to the same number of procedure-related euploid miscarriages as occurs with the integrated test (which is considered the optimum screening option for limiting the procedure related euploid miscarriages[@ref9]). With these cut-off values, contingent screening remains more cost effective than the integrated test and sequential screening. Our results are consistent with those of Wald et al,[@ref9] who reported that, with a first trimester cut-off point for high risk of 1 in 30, the number of procedure-related euploid miscarriages was greater in contingent and sequential screening options than in the integrated test, and that contingent screening, but not sequential screening, was more cost effective than the integrated test.[@ref9]

For contingent screening, the optimal cut-off value seems to be 1 in 9 cut-off with regard to cost effectiveness. The cut-off value of 1 in 30 showed the best cost effectiveness ratio, whereas the value of 1 in 6 produced the best incremental cost effectiveness ratio: hence, an in between value of 1 in 9 should achieve the best balance between these performance measures.

This value has important implications because the first trimester cut-off values traditionally used by healthcare professionals are much lower. Before the development of new screening strategies that combine first and second trimester tests,[@ref7] [@ref8] only the combined test (first trimester measurement of nuchal translucency, pregnancy associated plasma protein A, and β human chorionic gonadotrophin) used a first trimester cut-off value. The value for this test, which has become the de facto standard of care in the UK and may spread in North America,[@ref6] [@ref51] is 1 in 670 for obtaining a 90% detection rate.[@ref13] With strategies that combine first and second trimester tests,[@ref7] [@ref8] healthcare workers would have to be prepared (and trained) for the use of the much higher level of 1 in 9, and appropriate information would be needed for patients. Risk levels are often misunderstood by patients,[@ref52] and it may be difficult to refuse a diagnostic test at first trimester for an anxious woman with a calculated risk close to the 1 in 9 cut-off point because some women want an early diagnosis.[@ref38] [@ref39] However, the use of inappropriate cut-off values in the first trimester may produce an excess in iatrogenic losses and costs.

Different screening strategies
------------------------------

### Contingent screening

Our results confirm previous reports[@ref6] that contingent screening dominates all other options:

-   Best cost effectiveness for achieving a lower overall false positive rate leading to better outcomes

-   Fewer procedure related euploid miscarriages and unnecessary terminations

-   Lowest cost per case of Down's syndrome detected

-   Best incremental cost effectiveness ratio.

Contingent screening also offers early testing to those most likely to have an affected pregnancy (as does sequential screening), and it is the only option that allows the majority of women to be reassured early in gestation. Furthermore, it minimises costs by limiting retesting at the second trimester. Avoiding such repeat blood tests is a major reduction in unneeded clinic visits and their attendant costs. In our model, starting with 110 948 pregnancies, the removal of about 86 484 second clinic visits, blood draws, and reagent costs, results in major cost savings. Additionally, savings to the patients in terms of travel and time off work, are not to be ignored.[@ref5]

It has been proposed that all women who screen negative at the first trimester will still require screening at the second trimester for neural tube defects[@ref8] and that this may affect the cost effectiveness of contingent screening.[@ref9] However, this is not applicable in our study since the standard practice in Canada and similar countries is that all women undergo a fetal ultrasound assessment at 20 weeks of gestation,[@ref5] [@ref50] so that a second trimester test for serum α fetoprotein seems to be unnecessary.[@ref5]

### Sequential screening

In accordance with reported data,[@ref6] [@ref9] we found sequential screening to be outperformed by contingent screening. This is probably due to the high proportion of women who proceed to a second trimester test under the sequential screening scenario. However, the contingent and sequential screening options are very similar with regard to other outcomes.

### Integrated test

Our results confirm reports that the integrated test results in few procedure related euploid miscarriages[@ref9] and that its principal advantage is the low number of unnecessary terminations (because this screening option allows a diagnostic test only in the second trimester). However, the integrated test does not allow identification of affected pregnancies at the first trimester, nor reassurance for women with unaffected pregnancies. This could be a disadvantage given that women seem to want an early diagnosis.[@ref38] [@ref39]

### Triple test

Considering cost effectiveness and outcomes, triple test has too many limitations to be maintained as a desirable Down's syndrome screening strategy. But a screening option that starts in second trimester should also be available because one third of women seek prenatal care after the first trimester.[@ref7]

### Amniocentesis for women aged ≥35 years

We show here that scheduling an amniocentesis for women aged ≥35 years is not a cost effective strategy and should be abandoned rapidly. Also, this approach may produce seven times more procedure related euploid miscarriages than contingent screening.

What screening option?
----------------------

We conclude that, depending on local conditions,[@ref16] contingent screening is the preferred screening strategy for Down's syndrome with a first trimester cut-off value for risk of 1 in 9. Obviously, if it becomes possible to perform non-invasive prenatal diagnosis of Down's syndrome by means of fetal DNA or cells in maternal blood new cost effectiveness studies will be needed.[@ref12] [@ref53] [@ref54]

### What is already known on this topic

-   Prenatal screening for Down's syndrome is widely used, with many different screening strategies but still no consensus on the most cost effective approach

-   New strategies that provide a relatively high detection rate combine tests at both first and second trimesters

### What this study adds

-   For strategies that combine first and second trimester tests, the choice of cut-off value for risk in the first trimester test significantly influences the cost effectiveness ratios and outcomes

-   Contingent screening, with a first trimester cut-off value for high risk of 1 in 9, is the preferred option. This cut-off value is much higher than those generally used in screening programmes
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